Lauren Byers
Impact in
- Oncology top 0.1%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 135
- Lung Cancer Research Studies 82
- Cancer Immunotherapy and Biomarkers 20
- Peptidase Inhibition and Analysis 13
- PARP inhibition in cancer therapy 12
-
- Lung Cancer Treatments and Mutations 38
- Co-authors
- John Victor Heymach (58 shared papers)Charles M. Rudin (8 shared papers)Carl Michael Gay (30 shared papers)Don Lynn Gibbons (23 shared papers)Jing Wang (34 shared papers)Lixia Diao (34 shared papers)Ignacio Ivan Wistuba (19 shared papers)John Dorrance Minna (17 shared papers)
- Journals
- Journal of Thoracic Oncology (31 papers)Clinical Cancer Research (23 papers)Cancer Discovery (12 papers)Cancer Cell (9 papers)Cancer Research (9 papers)
- Partner nations
- United StatesUnited KingdomJapan
In The Last Decade
Lauren Byers
212 papers receiving 19.8k citations
Lauren Byers's Hit Papers
Peers
Comparison fields: 5 of 146
- Oncology 11.5k
- Cancer Research 2.8k
- Pulmonary and Respiratory Medicine 4.1k
- Immunology 2.7k
- Molecular Biology 7.3k
Countries citing papers authored by Lauren Byers
This map shows the geographic impact of Lauren Byers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauren Byers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauren Byers more than expected).
Fields of papers citing papers by Lauren Byers
This network shows the impact of papers produced by Lauren Byers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauren Byers. The network helps show where Lauren Byers may publish in the future.
Co-authors
The 25 scholars most cited alongside Lauren Byers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 219 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data Hit paper breakdown → | 2019 | 912 |
| 2 | An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance Hit paper breakdown → | 2012 | 850 |
| 3 | Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression Hit paper breakdown → | 2014 | 834 |
| 4 | Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Hit paper breakdown → | 2015 | 770 |
| 5 | Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer Hit paper breakdown → | 2019 | 715 |
| 6 | Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities Hit paper breakdown → | 2021 | 708 |
| 7 | Small cell lung cancer: Where do we go from here? Hit paper breakdown → | 2014 | 506 |
| 8 | Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial Hit paper breakdown → | 2021 | 488 |
| 9 | Integrative Molecular Characterization of Malignant Pleural Mesothelioma Hit paper breakdown → | 2018 | 480 |
| 10 | Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study Hit paper breakdown → | 2016 | 468 |
| 11 | 2012 | 451 | |
| 12 | Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome Hit paper breakdown → | 2012 | 433 |
| 13 | A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition Hit paper breakdown → | 2015 | 391 |
| 14 | 2018 | 390 | |
| 15 | 2016 | 374 | |
| 16 | 2017 | 341 | |
| 17 | 2020 | 340 | |
| 18 | 2018 | 335 | |
| 19 | 2009 | 304 | |
| 20 | 2019 | 287 |
About Lauren Byers
Lauren Byers is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Epidemiology, having authored 219 papers that have together received 20.0k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (82 papers), Lung Cancer Treatments and Mutations (38 papers), Neuroendocrine Tumor Research Advances (35 papers), Cancer therapeutics and mechanisms (20 papers), Cancer Immunotherapy and Biomarkers (20 papers), RNA modifications and cancer (15 papers), Peptidase Inhibition and Analysis (13 papers) and PARP inhibition in cancer therapy (12 papers). The work is most often cited by research in Oncology (11.5k citations), Cancer Research (2.8k citations), Pulmonary and Respiratory Medicine (4.1k citations), Immunology (2.7k citations) and Molecular Biology (7.3k citations). Lauren Byers has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include John Victor Heymach, Charles M. Rudin, Carl Michael Gay, Don Lynn Gibbons, Jing Wang, Lixia Diao, Ignacio Ivan Wistuba, John Dorrance Minna, Robert J. Cardnell and Triparna Sen. Their work appears in journals such as Journal of Thoracic Oncology, Clinical Cancer Research, Cancer Discovery, Cancer Cell and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.